Page 67 - Bio Engineering Approaches to Cancer Diagnosis and Treatment

References 65

[14] J. Wu, X. Li, W. Song, Y. Fang, L. Yu, S. Liu, et al. The roles and applications of autoan-
tibodies in progression, diagnosis, treatment and prognosis of human malignant tumours,
Autoimmun. Rev. 16 (12) (2017) 1270–1281.
[15] C. Desmetz, A. Mange, T. Maudelonde, J. Solassol, Autoantibody signatures: progress
and perspectives for early cancer detection, J. Cell. Mol. Med. 15 (10) (2011) 2013–2024.
[16] L. Dai, J.-C.J. Tsay, J. Li, T.-A. Yie, J.S. Munger, H. Pass, et al. Autoantibodies against tumor-
associated antigens in the early detection of lung cancer, Lung Cancer 99 (2016) 172–179.
[17] M. Kunizaki, T. Sawai, H. Takeshita, T. Tominaga, S. Hidaka, K. To, et al. Clinical value
of serum p53 antibody in the diagnosis and prognosis of colorectal cancer, Anticancer
Res. 36 (8) (2016) 4171–4175.
[18] Y. Liu, Y. Liao, L. Xiang, K. Jiang, S. Li, M. Huangfu, S. Sun, A panel of autoantibodies
as potential early diagnostic serum biomarkers in patients with breast cancer, Int. J. Clin.
Oncol. 22 (2) (2017) 291–296.
[19] L. Wu, W. Chang, J. Zhao, Y. Yu, X. Tan, T. Su, et al. Development of autoantibody sig-
natures as novel diagnostic biomarkers of non–small cell lung cancer, Clin Cancer Res.
16 (14) (2010) 3760–3768.
[20] H.T. Tan, J. Low, S.G. Lim, M.C. Chung, Serum autoantibodies as biomarkers for early
cancer detection, FEBS J. 276 (23) (2009) 6880–6904.
[21] Q. Xia, X.T. Kong, G.A. Zhang, X.J. Hou, H. Qiang, R.Q. Zhong, Proteomics-based iden-
tification of DEAD-box protein 48 as a novel autoantigen, a prospective serum marker
for pancreatic cancer, Biochem. Biophy. Res. Commun. 330 (2) (2005) 526–532.
[22] C.A. Borrebaeck, Precision diagnostics: moving towards protein biomarker signatures of
clinical utility in cancer, Nat. Rev. Cancer 17 (3) (2017) 199.
[23] F.X. Sutandy, J. Qian, C.S. Chen, H. Zhu, Overview of protein microarrays, Curr. Protocols
Protein Sci. 72 (1) (2013) 27.1.
[24] H.D. Shukla, Comprehensive analysis of cancer-proteogenome to identify biomarkers for
the early diagnosis and prognosis of cancer, Proteomes 5 (4) (2017) 28.
[25] B.S. Shruthi, P. Vinodhkumar, Selvamani, Proteomics: a new perspective for cancer, Adv.
Biomed. Res. 5 (2016) 67.
[26] P. Mertins, D.R. Mani, K.V. Ruggles, M.A. Gillette, K.R. Clauser, P. Wang, et al. Prote-
ogenomics connects somatic mutations to signalling in breast cancer, Nature 534 (7605)
(2016) 55.
[27] K.S. Anderson, N. Ramachandran, J. Wong, J.V. Raphael, E. Hainsworth, G. Demirkan,
et al. Application of protein microarrays for multiplexed detection of antibodies to tumor
antigens in breast cancer, J. Proteome Res. 7 (4) (2008) 1490–1499.
[28] C. Wingren, A. Sandström, R. Segersvärd, A. Carlsson, R. Andersson, M. Löhr, C.A.
Borrebaeck, Identification of serum biomarker signatures associated with pancreatic can-
cer, Cancer Res. 72 (10) (2012) 2481–2490.
[29] H. Srinivasan, Y. Allory, M. Sill, D. Vordos, M.S.S. Alhamdani, F. Radvanyi, et al. Predic-
tion of recurrence of non muscle-invasive bladder cancer by means of a protein signature
identified by antibody microarray analyses, Proteomics 14 (11) (2014) 1333–1342.
[30] M. Puig-Costa, A. Codina-Cazador, E. Cortés-Pastoret, C. Oliveras-Ferraros, S. Cufí,
S. Flaquer, et al. Discovery and validation of an INflammatory PROtein-driven GAstric
cancer Signature (INPROGAS) using antibody microarray-based oncoproteomics, Onco-
target 5 (7) (2014) 1942.
[31] X. Quan, Y. Ding, R. Feng, X. Zhu, Q. Zhang, Expression profile of cytokines in gastric
cancer patients using proteomic antibody microarray, Oncol. Lett. 14 (6) (2017) 7360–
7366.